PHE - Corporate - Sickle Cell and Thalassaemia Screening Programme
Minimum acceptable performance criteria for designing test accuracy studies of cfDNA within the UK Sickle Cell and Thalassaemia Screening Programme: a decision analytic model.
Buyer
Public Health England
Value
£80,464
Published
17 Aug 2021
Closes
20 Jul 2021
Procurement details
Source
Contracts Finder
Region
United Kingdom
Procurement method
Other
Category
Services
Contract starts
16 Aug 2021
Contract ends
30 Dec 2022
CPV classifications
75122000
Administrative healthcare services
Lots
Lot default PHE - Corporate - Sickle Cell and Thalassaemia Screening Programme
£80,464
Minimum acceptable performance criteria for designing test accuracy studies of cfDNA within the UK Sickle Cell and Thalassaemia Screening Programme: a decision analytic model.
Delivery: United Kingdom
Documents
Unlock document linkAwarded contract notice on Contracts Finder
17 Aug 2021
Awarded contract notice on Contracts Finder
Award notice · Web page
Contains public sector information licensed under the Open Government Licence v3.0.